GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » E10

Advaxis (Advaxis) E10 : $-1,665.76 (As of Mar. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Advaxis E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Advaxis's adjusted earnings per share data for the three months ended in Mar. 2023 was $-1.670. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1,665.76 for the trailing ten years ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-27), Advaxis's current stock price is $0.555. Advaxis's E10 for the quarter that ended in Mar. 2023 was $-1,665.76. Advaxis's Shiller PE Ratio of today is .


Advaxis E10 Historical Data

The historical data trend for Advaxis's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis E10 Chart

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,623.46 -4,852.25 -3,360.41 -2,559.57 -1,900.73

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,229.67 -2,104.52 -1,972.40 -1,900.73 -1,665.76

Competitive Comparison of Advaxis's E10

For the Biotechnology subindustry, Advaxis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advaxis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advaxis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Advaxis's Shiller PE Ratio falls into.



Advaxis E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Advaxis's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-1.67/127.3478*127.3478
=-1.670

Current CPI (Mar. 2023) = 127.3478.

Advaxis Quarterly Data

per share eps CPI Adj_EPS
201304 -1,547.990 98.107 -2,009.362
201307 -443.998 98.557 -573.703
201310 -1,163.990 98.536 -1,504.347
201401 -443.998 98.692 -572.917
201404 -179.999 100.023 -229.172
201407 -359.998 100.520 -456.077
201410 -179.999 100.176 -228.823
201501 -395.998 98.604 -511.437
201504 -623.997 99.824 -796.051
201507 -527.997 100.691 -667.780
201510 -455.998 100.346 -578.699
201601 -707.996 99.957 -902.002
201604 -539.997 100.947 -681.224
201607 -575.997 101.524 -722.512
201610 -671.997 101.988 -839.092
201701 -515.997 102.456 -641.357
201704 -611.997 103.167 -755.438
201707 -959.995 103.278 -1,183.732
201710 -683.997 104.070 -836.991
201801 -587.997 104.578 -716.024
201804 -322.400 105.708 -388.399
201807 -319.200 106.324 -382.316
201810 -350.400 106.695 -418.227
201901 220.800 106.200 264.768
201904 -127.200 107.818 -150.240
201907 -80.000 108.250 -94.114
201910 -16.235 108.577 -19.042
202001 -12.000 108.841 -14.040
202004 -8.000 108.173 -9.418
202007 -7.200 109.318 -8.388
202010 -6.400 109.861 -7.419
202101 -4.000 110.364 -4.616
202104 -3.320 112.673 -3.752
202107 -1.830 115.183 -2.023
202110 -3.030 116.696 -3.307
202201 -0.200 118.619 -0.215
202204 -1.900 121.978 -1.984
202207 -3.830 125.002 -3.902
202210 -2.530 125.734 -2.562
202303 -1.670 127.348 -1.670

Add all the adjusted EPS together and divide 10 will get our e10.


Advaxis  (OTCPK:ADXS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Advaxis E10 Related Terms

Thank you for viewing the detailed overview of Advaxis's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070